fda ghk-cu immunogenicity risk adds non-injectable back to Category 1. FDA Thursday re-added FDA to Review Seven Peptides

Collection of fractions every 10-30 min for LC-MS/MS or HPLC quantification

Factors affecting response include: Duration of hair loss (recent loss responds better than long-standing)

The findings suggest that specimens exposed to the GHK-Cu peptide complex may exhibit better-supported tissue organization and repair-associated characteristics relative to comparator groups

GHK-Cu peptide therapy represents one of those solutions, backed by solid mechanistic science and decades of research, that mainstream medicine ignores because theres no patent profit in a naturally occurring peptide

Animal Toxicology Studies Animal toxicology studies tested doses from 0.0027 mg/lb to 9.1 mg/lb via intraperitoneal, intramuscular, intravenous, and oral routes for up to 6 weeks, finding: No acute toxic or lethal dose No gross or histologic toxicity in major organs No hepatotoxicity or nephrotoxicity Negative Ames test (no mutagenicity) Negative chromosomal aberration tests (no genotoxicity) No teratogenicity in rat pregnancy studies No local injection site irritation The LD1 (minimum lethal dose) could not be achieved despite aggressive testing